![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Vaniprevir (MK-7009) Demonstrates Higher Exposures in Treatment-Experienced Genotype (GT) 1 Cirrhotic Than Non-cirrhotic HCV-Infected Patients
|
|
|
Reported by Jules Levin
AASLD 2013 Nov 1-5 Wash DC
Wei Gao, Luzelena Caro, Melanie Anderson, Peggy May Tan Hwang, Amy Zhou, Jing Su, Niloufar Mobashery
Merck Research Laboratories, Merck & Co., Inc., Whitehouse, NJ
![AASLD1.gif](../images/120113/120213-2/AASLD1.gif)
![AASLD2.gif](../images/120113/120213-2/AASLD2.gif)
![AASLD3.gif](../images/120113/120213-2/AASLD3.gif)
![AASLD4.gif](../images/120113/120213-2/AASLD4.gif)
![AASLD5.gif](../images/120113/120213-2/AASLD5.gif)
![AASLD6.gif](../images/120113/120213-2/AASLD6.gif)
![AASLD7.gif](../images/120113/120213-2/AASLD7.gif)
![AASLD8.gif](../images/120113/120213-2/AASLD8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|